The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease
- PMID: 10974186
- DOI: 10.1016/s0002-9343(00)00474-5
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease
Abstract
Platelet membrane glycoprotein IIb/IIIa inhibitors, a new class of potent antiplatelet agents, have been used in the treatment of acute coronary syndromes as well as in the prevention of complications after percutaneous coronary interventions. Approximately 50,000 patients with coronary artery disease have been enrolled in randomized studies of glycoprotein IIb/IIIa inhibitors. The purpose of this article is to review the pharmacology of glycoprotein IIb/IIIa inhibitors, the results of the clinical trials using these agents, and their current use in percutaneous coronary interventions and the treatment of acute coronary syndromes.
Comment in
-
Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.Am J Med. 2000 Aug 15;109(3):252-4. doi: 10.1016/s0002-9343(00)00527-1. Am J Med. 2000. PMID: 10974193 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical